Pfizer Reports Results of 20vPnC in P-III Trial for the Prevention of Invasive Pneumococcal Disease

Published: Aug 12, 2022 | Tags: Pfizer, 20vPnC, Invasive Pneumococcal Disease, Clinical Trial, P-III

Daiichi Sankyo and AstraZeneca’s Enhertu Receives the US FDA’s Approval for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung Cancer

Published: Aug 12, 2022 | Tags: Daiichi Sankyo, AstraZeneca, Enhertu, HER2 Mutant Metastatic Non-Small Cell Lung Cancer, Regulatory, US, FDA, P-II, DESTINY-Lung02

Argenx’s Vyvgart Receives the EC’s Approval for the Treatment of Generalized Myasthenia Gravis

Published: Aug 12, 2022 | Tags: Argenx, Vyvgart, Generalized Myasthenia Gravis, Regulatory, EU, US, FDA, Japan, China, Canada, P-III, ADAPT

BridgeBio, Sentynl, and Medison Reports the Approval of Nulibry in Israel for the Treatment of Molybdenum Cofactor Deficiency Type A

Published: Aug 12, 2022 | Tags: BridgeBio, Sentynl, Medison, Nulibry, Molybdenum Cofactor Deficiency Type A, Regulatory, US, FDA, EMA, CHMP

Abbott Reports Study Results Evaluating the i-STAT TBI Plasma Test for the Prediction of the Outcomes Due to Brain Injury

Published: Aug 12, 2022 | Tags: Abbott, i-STAT TBI Plasma Test, Brain Injury, Clinical Trial, US, FDA, Alinity I, ARCHITECT

BMS Entered into a Collaboration with GentiBio for the Development of New Treg Therapies Against Inflammatory Bowel Diseases

Published: Aug 12, 2022 | Tags: BMS, GentiBio, Treg Platform, Inflammatory Bowel Diseases, Pharma, Immunology, Autoimmune Diseases

Gamida Cell Reports First Patient Dosing in P-I/II Study of GDA-201 for the Treatment of Follicular and Diffuse Large B Cell Lymphoma

Published: Aug 10, 2022 | Tags: Gamida Cell, GDA-201, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Clinical Trials

Just-Evotec Biologics Expands its Partnership with Alpine Immune Sciences for the Commercial Process Development of ALPN-303 to Treat Systemic Lupus Erythematosus

Published: Aug 10, 2022 | Tags: Just-Evotec Biologics, Alpine Immune Sciences, ALPN-303, J.DESIGN, Systemic Lupus Erythematosus, Inflammatory Disease, Autoimmune Diseases, Pharma, P-I & P-II

Innovent’s Picankibart (IBI112) Meet its Primary Endpoint in the P-II (CIBI112A201) Study for the Treatment of Plaque Psoriasis

Published: Aug 10, 2022 | Tags: Innovent, Picankibart, IBI112, Plaque Psoriasis, Clinical trials, P-II, CIBI112A201 Study

AstraZeneca and Daiichi Sankyo Present P-Ib (TROPION-Lung02) Trial Results of Datopotamab Deruxtecan (Dato-DXd) for Advanced NSCLC at WCLC 2022

Published: Aug 10, 2022 | Tags: AstraZeneca, Daiichi Sankyo, Datopotamab deruxtecan, Dato-DXd, Advanced NSCLC, P-Ib TROPION-Lung02 Trial, WCLC, 2022

Merck Entered into a Multi-Year Strategic Research Collaboration with Cerevance to Discover Novel Targets Using NETSseq Technology for Alzheimer’s Disease

Published: Aug 10, 2022 | Tags: Merck, Cerevance, Novel Targets, Alzheimer’s Disease, Pharma

GSK Entered into an Option Agreement with Mersana to Co-Development and Commercialize XMT-2056 for the Treatment of Cancer

Published: Aug 10, 2022 | Tags: GSK, Mersana, XMT-2056, Cancer, HER2-expressing tumors, Pharma

Eli Lilly Reports the Availability of Taltz (ixekizumab) as New Citrate-Free Formulation to Reduce Injection Site Pain in the US

Published: Aug 8, 2022 | Tags: Eli Lilly, Taltz, ixekizumab, Citrate-Free Formulation, Injection Site Pain, Regulatory

HUTCHMED and AstraZeneca Report P-II (SAVANNAH) Trial Results of Tagrisso + Savolitinib for EGFR-Mutated NSCLC

Published: Aug 8, 2022 | Tags: HUTCHMED, AstraZeneca, Tagrisso, Savolitinib, EGFR-Mutated NSCLC, P-II SAVANNAH Trial

HUTCHMED Reports P-III (FRESCO-2) Trial Results of Fruquintinib for the Treatment of Metastatic Colorectal Cancer

Published: Aug 8, 2022 | Tags: HUTCHMED, Fruquintinib, Metastatic Colorectal Cancer, P-III, FRESCO-2 Trial

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) Receive the US FDA’s Approval as First HER2-Directed Therapy for HER2-low Metastatic Breast Cancer

Published: Aug 8, 2022 | Tags: AstraZeneca, Daiichi Sankyo, Enhertu, trastuzumab deruxtecan, HER2-low Metastatic Breast Cancer, Regulatory, US, FDA, Approval

Genmab Expands its 2015 Agreement with BioNTech to Develop and Commercialize Novel Immunotherapy for Cancer

Published: Aug 8, 2022 | Tags: Genmab, BioNTech, Novel Immunotherapy, GEN1053, GEN1046, Cancer, HexaBody technology, Biotech

Myovant and Pfizer’s Myfembree Receive the US FDA’s Approval for the Treatment of Pain Associated with Endometriosis

Published: Aug 8, 2022 | Tags: Myovant Sciences, Pfizer, Myfembree, Pain, Endometriosis, Regulatory, US, FDA, Approval

Related Post: PharmaShots Weekly Snapshots (August 1 – 5, 2022)